VCYT logo

Veracyte Inc. (VCYT)

$49.94

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on VCYT

Market cap

$3.98B

EPS

1.08

P/E ratio

30.7

Price to sales

4.85

Dividend yield

--

Beta

1.982698

Price on VCYT

Previous close

$48.69

Today's open

$49.30

Day's range

$48.70 - $50.54

52 week range

$22.61 - $50.71

Profile about VCYT

CEO

Marc Stapley

Employees

755

Headquarters

South San Francisco, CA

Exchange

NASDAQ Global Market

Shares outstanding

79792647

Issue type

Common Stock

VCYT industries and sectors

Healthcare

Medical Diagnostics & Screening

News on VCYT

Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?

Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?

news source

Zacks Investment Research • Jun 4, 2026

news preview

Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript

Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript

news source

Seeking Alpha • Jun 1, 2026

news preview

Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #BreastCancer--Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

news source

Business Wire • Jun 1, 2026

news preview

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer.

news source

Business Wire • May 30, 2026

news preview

Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte's Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--OPTIMA Trial Delivers Practice-Changing Evidence that Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemo.

news source

Business Wire • May 29, 2026

news preview

Veracyte: The Evidence Flywheel Is Turning Into A Cash Flow Platform

Veracyte is evolving into a multi-cancer clinical decision-making platform, leveraging evidence, payer coverage, and workflow integration for durable growth. Q1 2026 results showed 21% revenue growth, expanding gross margins (up to 76% non-GAAP), and strong operating leverage, with raised 2026 guidance and robust cash generation. Medicare coverage for TrueMRD in muscle-invasive bladder cancer and the upcoming Prosigna LDT launch in breast cancer expand VCYT's addressable market and reinforce its evidence-driven moat.

news source

Seeking Alpha • May 28, 2026

news preview

Veracyte genomic test identifies breast cancer patients who can skip chemo

Today we feature studies to be presented at the year's most important cancer conference, the upcoming American Society of Clinical Oncology meeting in Chicago, all with the potential to be ​practice-changing.

news source

Reuters • May 27, 2026

news preview

Is it Worth Retaining Veracyte Stock in Your Portfolio for Now?

VCYT gains from strong Afirma and Decipher test growth, but macro pressures and competition pose risks. See what may shape its next move.

news source

Zacks Investment Research • May 27, 2026

news preview

Here's Why Veracyte (VCYT) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

news source

Zacks Investment Research • May 25, 2026

news preview

Veracyte Stock Surges 65.8% in a Year: What's Driving the Rally?

VCYT jumps 65.8% in a year as Afirma and Decipher volumes surge, guidance lifts, and TrueMRD nears launch with $439M cash and no debt.

news source

Zacks Investment Research • May 25, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Veracyte Inc.

Open an M1 investment account to buy and sell Veracyte Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in VCYT on M1